{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-031796","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.539551+00:00","generated_at":"2026-06-21T05:49:43.247297+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Champions Oncology reports record Q2 revenue of $14.3M, cuts FY growth outlook to 10-15%","bullets":["Record quarterly revenue of $14.3M, up 21% YoY from $11.8M.","Adjusted EBITDA of $686K, down from $743K in prior-year period.","Operating income just $7K; gross margin fell to 48% from 52%.","Full-year growth target revised to 10%-15% due to increased cancellations and economic slowdown.","Cash on hand $10.8M, no debt; cash from operations $3.3M for the quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-031796","json":"https://secwatch.observer/filing/0001628280-22-031796.json","markdown":"https://secwatch.observer/filing/0001628280-22-031796.md","text":"https://secwatch.observer/filing/0001628280-22-031796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828022031796/0001628280-22-031796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828022031796/csbr-20221213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:49:43.247297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6f2b75d6886351fa972b5e65e2e7b61a5fcfbec0","claim":"CHAMPIONS ONCOLOGY, INC. reported second quarter of fiscal 2023, ended October 31, 2022 results: revenue $14.3 million. Guidance lowered.","evidence_excerpt":"in such a filing. --- EX-99.1 (EX-99.1) --- NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $14.3 Million Hackensack, NJ – December 13 , 2022 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828022031796/0001628280-22-031796-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of fiscal 2023, ended October 31, 2022"},{"label":"Revenue","value":"$14.3 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}